Technical Analysis for BBIO - BridgeBio Pharma, Inc.

Grade Last Price % Change Price Change
D 52.12 5.59% 2.76
BBIO closed up 5.59 percent on Friday, September 17, 2021, on 3.38 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical BBIO trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Bollinger Band Squeeze Range Contraction 5.59%
BB Squeeze + Lower Band Touch Range Contraction 5.59%
Lower Bollinger Band Touch Weakness 5.59%
Bollinger Band Squeeze Range Contraction 7.55%
Fell Below 20 DMA Bearish 6.96%
Older End-of-Day Signals for BBIO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 21 hours ago
10 DMA Resistance 1 day ago
Up 2% 1 day ago
60 Minute Opening Range Breakout 1 day ago
Rose Above 20 DMA 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BridgeBio Pharma, Inc. Description

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Organ Systems Anatomy Tyrosine Kinase Receptors Tyrosine Kinase Amyloid Amyloidosis Myopathy Cardiomyopathy Fibroblast Growth Factor Receptor Hyperplasia Protein Kinase Inhibitor Transthyretin Familial Amyloid Polyneuropathy Polyneuropathy Achondroplasia Congenital Adrenal Hyperplasia TTR Amyloidosis

Is BBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 73.5
52 Week Low 36.2
Average Volume 754,205
200-Day Moving Average 59.39
50-Day Moving Average 53.36
20-Day Moving Average 50.13
10-Day Moving Average 50.39
Average True Range 2.07
ADX 26.41
+DI 17.86
-DI 21.27
Chandelier Exit (Long, 3 ATRs) 46.18
Chandelier Exit (Short, 3 ATRs) 52.97
Upper Bollinger Bands 52.20
Lower Bollinger Band 48.06
Percent B (%b) 0.98
BandWidth 8.25
MACD Line -0.68
MACD Signal Line -0.98
MACD Histogram 0.2947
Fundamentals Value
Market Cap 6.39 Billion
Num Shares 123 Million
EPS -10.90
Price-to-Earnings (P/E) Ratio -4.78
Price-to-Sales 259.96
Price-to-Book 36.28
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.42
Resistance 3 (R3) 55.96 54.08 55.70
Resistance 2 (R2) 54.08 52.98 54.30 55.46
Resistance 1 (R1) 53.10 52.31 53.59 53.55 55.22
Pivot Point 51.21 51.21 51.46 51.44 51.21
Support 1 (S1) 50.23 50.12 50.72 50.69 49.02
Support 2 (S2) 48.35 49.44 48.57 48.78
Support 3 (S3) 47.37 48.35 48.54
Support 4 (S4) 47.82